Stoke Therapeutics, Inc. (STOK) — Financial statements
Income statement, balance sheet, and cash flow for Stoke Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 184↑404.5% | 37↑316.3% | 9↓29.2% | 12 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 184↑404.5% | 37↑316.3% | 9↓29.2% | 12 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 138↑54.7% | 89↑8.4% | 82↑5.6% | 78↑43.7% | 54 | |
| General & Administrative Expenses | 67↑37.5% | 49↑18.1% | 41↑6.2% | 39↑22.0% | 32 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 67↑37.5% | 49↑18.1% | 41↑6.2% | 39↑22.0% | 32 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 205↑48.6% | 138↑11.6% | 124↑5.8% | 117↑35.7% | 86 | |
| Total Costs & Expenses | 205↑48.6% | 138↑11.6% | 124↑5.8% | 117↑35.7% | 86 | |
| Operating Results | ||||||
| Operating Income | -21↑79.7% | -101↑11.7% | -115↓10.0% | -104↓21.3% | -86 | |
| Depreciation & Amortization | 2↓18.7% | 2↓11.8% | 2↑59.7% | 2↑58.7% | 0.97 | |
| EBITDA | -19↑81.0% | -99↑11.7% | -112↓9.2% | -103↓20.8% | -85 | |
| EBIT | -21↑79.7% | -101↑11.7% | -115↓10.0% | -104↓21.3% | -86 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.12 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.12 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 14↑10.6% | 12↑23.0% | 10↑206.3% | 3↑1165.0% | 0.26 | |
| Income Before Tax | -7↑92.3% | -89↑15.0% | -105↓3.6% | -101↓17.8% | -86 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -7↑92.3% | -89↑15.0% | -105↓3.6% | -101↓17.8% | -86 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -7↑92.3% | -89↑15.0% | -105↓3.6% | -101↓17.8% | -86 | |
| Bottom-Line Net Income | -7↑92.3% | -89↑15.0% | -105↓3.6% | -101↓17.8% | -86 | |
| EPS (Basic) | -0.12↑92.7% | -1.65↑30.7% | -2.38↑8.5% | -2.60↓11.1% | -2.34 | |
| EPS (Diluted) | -0.12↑92.7% | -1.65↑30.7% | -2.38↑8.5% | -2.60↓11.1% | -2.34 | |
| Weighted Average Shares | 59↑9.6% | 54↑22.8% | 44↑13.1% | 39↑5.9% | 37 | |
| Weighted Average Diluted Shares | 59↑9.6% | 54↑22.8% | 44↑13.1% | 39↑5.9% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.